Debarment
Debarment is a penalty set forth under the Food and Drugs Act,[1] which the U.S. Food and Drug Administration can, and sometimes must, impose on persons or companies that engage in criminal conduct with respect to the development or approval of new drugs. The penalty itself is a prohibition against that person or company from submitting or assisting in the submission of such an application.
As of April 2009, the FDA has debarred 73 persons, of which all but 9 were permanently debarred.[2] The FDA has never debarred a company.[2]
Constitutional issues
In the earliest debarment cases, following the passage of the laws permitting the imposition of this penalty, the penalty was imposed on persons who had committed the offending acts had done so prior to the passage of those laws. They therefore argued that the application of this penalty to them was an unconstitutional ex post facto application of the law. Another constitutional issue raised was double jeopardy, it being argued that persons who had been tried, convicted, and sentenced to a particular punishment by a court of law could not be further penalized for the same offense. The courts rejected these arguments based on the finding that debarment was not intended as a punishment, but rather as a means of protecting the public from persons who had exhibited the capacity for engaging in such conduct.[3]
References
- ^ 21 U.S.C. 335a(a)-(g).
- ^ a b U.S. Food and Drug Administration debarment list, last visited April 21, 2009.
- ^ Bae v. Shalala, 44 F.3d 489 (7th Cir. 1995); DiCola v. FDA, 77 F.3d 504 (D.C. Cir. 1996); Bhutni v. FDA, 161 Fed. Appx. 589 (7th Cir. 2006).
External links
